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chemotherapyAbstract Tuberculosis (TB) is a public health challenge worldwide and advancement of latent TB
to active disease and drug resistant TB is on the increase as a result of immune suppression induced
by Mycobacterium tuberculosis. There are empirical evidences relating immune suppression and
malnutrition. To improve the management strategy of TB patients, this study determined micronu-
trient concentrations in TB patients and established duration (months) post commencement of anti-
tuberculosis (anti-TB) chemotherapy that is most important for micronutrient supplementation.
Plasma iron, zinc, copper, vitamins A, C, D and E were determined in twenty-four (24) active
tuberculosis patients at diagnosis, 2 months, 4 months and 6 months post-commencement of
anti-TB chemotherapy, as well as twenty (20) healthy controls. Plasma concentrations of the
micronutrients iron, zinc, copper, vitamins A, C, D and E were signiﬁcantly reduced in TB patients
at diagnosis and throughout the period of treatment when compared to controls. Plasma zinc and
copper levels were signiﬁcantly increased at 4 months and 6 months of drug therapy when
compared with levels at diagnosis whereas plasma iron was signiﬁcantly reduced at 4 months of
treatment compared with their levels at diagnosis. Vitamins A, C, D and E in TB patients were
signiﬁcantly reduced at 2 months and 4 months of treatment compared to diagnosis.rculosis.
676 V.F. Edem et al.This study concluded that there is micronutrient (Fe, Zn, Cu, Vit A, C, D and E) malnutrition in
tuberculosis patients at diagnosis and throughout the duration (6 months) of chemotherapy.
Supplementation with vitamins and zinc is advised within the ﬁrst 4 months of commencing anti-
tuberculosis chemotherapy.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Tuberculosis (TB) remains a major global health challenge
with 8.7 million new cases and 1.4 million deaths annually
[1]. Approximately one third of the world’s population is
latently infected with Mycobacterium tuberculosis (Mtb), the
etiologic agent of TB. Latently Mtb infected immuno-
competent individuals have a 10% lifetime chance of reactiva-
tion to active disease but higher chance (up to 90%) of
reactivation to active TB in immuno-compromised individuals
[2]. About 60% of all TB cases occur in Africa and South East
Asia [2], and this has been associated with extreme poverty,
malnutrition, poor hygiene and HIV infection which predis-
poses to immunosuppression [3].
Mtb establishes and expands infection within resident
alveolar macrophages by subverting the natural killing mecha-
nism of these cells. Generation of reactive oxygen intermedi-
ates (ROI) and reactive nitrogen intermediates (RNI) via
respiratory burst pathway following bacilli phagocytosis plays
an important role in pathogen clearance [4]. Some trace
elements have been identiﬁed to play important roles in macro-
phage phagocytosis, ROI and RNI generation, intracellular
killing as well as eventual bacterial clearance [5]. Vitamins A,
C, D and E have been described as immune enhancers in dif-
ferent infectious diseases including TB, and supplementation
of these vitamins has been shown to boost immunity [6]. But
the mechanism by which this is achieved is largely unclear.
Iron and copper propagate the formation of toxic hydroxyl
radical in a Fenton and Fenton-like chemistry, respectively
[7,8] and their deﬁciencies have been associated with mod-
ulation of immune responses [5]. Furthermore, the immune
modulatory effects of zinc are well documented [9].
There is epidemiological evidence of an association between
malnutrition and development of active TB in latently infected
individuals [10]. Active tuberculosis is associated with wasting
as a result of anorexia, reduced food intake and mal-absorp-
tion [11]. Before the advent of anti-tuberculosis (anti-TB)
chemotherapy, a diet rich in calories, proteins, fats, minerals
and vitamins was considered in the treatment of tuberculosis
[12]. However, introduction of anti-TB drugs led to reduced
emphasis on the importance of nutritional support in the man-
agement of TB patients. In Nigeria, newly diagnosed TB
patients are treated for at least 6 months with anti-TB therapy
without reference to the micronutrient status of these patients
pre-, during and post-therapy.
Therefore, the objective of this study is to determine the
levels of nutritionally essential trace elements (Fe, Zn and
Cu) and vitamins (Vit A, C, D and E) in plasma of TB patients
before and during drug regimen. The aim is to establish
micronutrient malnutrition in TB patients and to establish
for the ﬁrst time which duration (months) post commencement
of anti-TB drug therapy is in the micronutrient level mostaffected. It is the opinion of the authors that the outcome will
improve TB patients’ management or reduce advancement of
pulmonary tuberculosis (PTB) to drug resistant TB.
Participants and methods
Forty-four (44) participants were recruited for the study which
comprised of twenty-four (24) newly diagnosed pulmonary
tuberculosis (PTB) patients and twenty (20) non-PTB
apparently healthy subjects after obtaining written informed
consent. The study protocol was reviewed and approved by
the University of Ibadan/University College Hospital joint
Institutional Research Ethics Committee. All patients were
recruited from the Medicine Out-patient Clinic, University
College Hospital, Ibadan, Nigeria by a consultant Chest
Physician after laboratory tests, chest X-ray and clinical
history.
Five milliliters of blood was withdrawn from the anti cubi-
tal fossa vein into lithium heparin tubes at diagnosis, 2 months
of anti-TB therapy, 4 months of anti-TB therapy and at
completion of duration of anti-TB therapy (6 months). Blood
samples were centrifuged and plasma collected were analyzed.
Micronutrient analysis
Plasma levels of micronutrient vitamins (A, C, D and E) were
determined by high performance liquid chromatography
method using WATERS 616/626 (USA) machine as previously
carried out [13].
Plasma concentrations of trace metals (Fe, Zn and Cu) were
determined using atomic absorption spectrophotometry (Buck
Scientiﬁc, 210, Atomic Absorption Spectrophotometer,
Connecticut, USA) as previously described [14].
Statistical analysis
The data obtained were analyzed using statistical package for
social sciences (SPSS) version 17.0. Independent Student t-test
was used to compare the mean values between PTB patients
and controls while paired t-test was used to compare the mean
values of PTB patients at diagnosis, 2 months, 4 months and
6 months of anti-TB regimen. Values were considered signiﬁ-
cant at p< 0.05.
Results
Plasma concentrations of the micronutrients iron, zinc,
copper, vitamin A, vitamin C, vitamin D and vitamin E were
signiﬁcantly reduced in TB patients at diagnosis and through-
out the period of treatment when compared to controls
(Table 1).
Table 1 Plasma concentrations of micronutrients in TB patients at diagnosis and during treatment, and healthy controls.
Parameters At diagnosis 2 months 4 months 6 months Control
Iron (lg/dl) 109.39 ± 17.6* 110.02 ± 7.9* 85.39 ± 23.7*,o 105.10 ± 19.1* 143.2 ± 5.9
Zinc (lg/dl) 81.29 ± 22.3* 79.53 ± 11.3* 92.41 ± 9.7*,o 118.94 ± 25.8*,o 148.3 ± 31.7
Copper (lg/dl) 104.8 ± 25.3* 96.11 ± 18.3* 139.68 ± 18.1*,o 145.85 ± 18.1*,o 160.4 ± 25.2
Vitamin A (lg/dl) 72.9 ± 11.8* 62.53 ± 11.8*,o 59.96 ± 9.8*,o 71.80 ± 10.0* 84.6 ± 10.1
Vitamin C (mg/dl) 0.74 ± 0.12* 0.59 ± 0.08*,o 0.61 ± 0.10*,o 0.74 ± 0.10* 0.87 ± 0.1
Vitamin D (pg/ml) 58.1 ± 9.8* 46.36 ± 6.2*,o 48.56 ± 7.9*,o 58.15 ± 8.1* 68.5 ± 8.2
Vitamin E (mg/dl) 1.1 ± 0.2* 0.86 ± 0.1*,o 0.89 ± 0.1*,o 1.08 ± 0.2o 1.27 ± 0.2
* Signiﬁcantly different from control.
o Signiﬁcantly different from diagnosis.
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increased at 4 months and 6 months of drug therapy when
compared with their levels at diagnosis whereas mean plasma
iron was signiﬁcantly reduced at 4 months of treatment when
compared to their levels at diagnosis (Table 1). Vitamins A,
C, D and E in plasma of TB patients were signiﬁcantly reduced
at 2 months and 4 months of treatment when compared to the
plasma concentrations at diagnosis (Table 1). There were no
differences in the mean plasma concentrations of vitamins A,
C, D and E at completion of treatment (6 months) compared
to diagnosis (Table 1).
Also from Table 1, plasma iron and vitamin A were lowest
at 4 months of treatment while plasma zinc, copper, vitamin C,
vitamin D and vitamin E were lowest at 2 months of
treatment.
Discussion
Nutritional status is an important determinant of resistance to
infection, and malnutrition remains a major cause of immuno-
suppression worldwide [15]. In this present study, the plasma
concentrations of iron, zinc, copper, vitamin A, vitamin C,
vitamin D and vitamin E were low in TB patients at diagnosis
and throughout the period of anti-TB therapy when compared
to controls. This is consistent with previously reported bidirec-
tional interaction between TB and malnutrition [11]. The
observed signiﬁcantly low micronutrient status in TB patients
might be due to loss of appetite, nausea and vomiting caused
by anti-TB drugs or anorexia, impaired absorption of nutrients
or increased catabolism as previously proposed by Karyadi
et al. [16]. Our result is suggestive of the need for nutritional
support in the management of TB patients.
Low iron concentration in TB patients observed in this
study supports the ﬁndings of Kassu et al. [17] among
Ethiopian TB patients. This decrease might be explained by
increased blood loss from hemoptysis in TB patients or due
to the body’s defense mechanism to create an iron-scarce
environment limiting Mtb growth and expansion. Although
iron has been reported to play a signiﬁcant role in
myeloperoxidase-dependent generation of hypochlorous acid
(a microbicidal factor), there is a need for caution in
recommending dietary iron supplementation for TB patients
because free iron is used by bacteria for replication. In a
prospective study of the relationship between TB and increased
dietary iron, increased dietary iron was associated with a
3.5-fold increase in estimated odds of developing active TB
and a trend toward higher mortality among TB patients [18].Thus, giving iron containing supplements to TB patients
should be done with caution.
Zinc is crucial for normal development and function of cells
mediating non-speciﬁc immunity. Zinc and copper are also
linked in the respiratory burst pathway as prosthetic compo-
nents of the enzyme super oxide dismutase (Cu–Zn SOD).
The low zinc level reported in TB patients is in concert with
reports from Ethiopia [17], Turkey [19], Ecuador [16] and
India [20]. The low plasma zinc in TB patients compared with
control was probably due to redistribution of zinc from blood
circulation to other tissues, reduction in hepatic production of
a2-macroglobulin (a zinc carrier protein) or a rise in the pro-
duction of metallothionein, which is a protein that transports
zinc to the liver. This study observed reduced plasma copper
in TB patients when compared to controls. This is in contrast
with previous studies [17,19,21]. Our ﬁnding of low copper in
TB patients might be due to increased utilization of copper
by macrophages and Mtb. Previous reports have demonstrated
that macrophages take-up copper in response to Mtb infection
and that Mtb requires copper for survival [22]. Hence, giving
copper containing supplements to TB patients should also be
done with caution. Zinc and copper are components of an
enzyme (superoxide dismutase) of the respiratory burst path-
way. Superoxide dismutase is responsible for production of
hydrogen peroxide, a potent factor of intracellular killing
mechanism by phagocytes (especially macrophages and neu-
trophils). It is therefore likely that reduced plasma zinc and
copper in PTB patients may lead to low production of reactive
oxygen species thus increasing susceptibility of TB patients to
intracellular pathogens or aggravating advancement of TB.
Investigation of intracellular killing in TB patients is therefore
suggested.
Studies have shown that vitamins signiﬁcantly alter macro-
phage phagocytosis [5]. The role of vitamin D in resistance and
treatment of active TB has been extensively studied. Vitamin D
rich cod liver oil and exposure to sunlight were once part of
regular therapy for TB [23]. Vitamin D is required for macro-
phage activation and increases production of antimicrobial
peptide cathelicidin, which is essential for keeping TB in the
latent phase and limiting growth and expansion of Mtb [24].
In addition, vitamin D down-regulates the transcription of a
substance that is needed for the intracellular survival of TB
bacillus in macrophages [25,26]. Vitamin C has also been
demonstrated to kill drug-sensitive and drug-resistant strains
of Mtb via the Fenton reaction pathway by acting as a pro-
oxidant [27]. Vitamin E (a-tocopherol) on the other hand is
known to react with reactive species to form a-tocopheroxyl
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effects potentiate bacterial clearance. Furthermore, vitamins
A, C and E through their antioxidant functions moderate
oxidative stress which has been reported in TB patients
[28–30]. This study found low plasma concentrations of
vitamins A, C, D and E in TB patients at diagnosis and
throughout the period of treatment. Low vitamins A, C, D
and E in TB patients at diagnosis compared to non-TB
patients corroborates with the ﬁndings of Rohini et al. [20]
and Karyadi et al. [16]. These ﬁndings may be due to increased
urinary excretion, reduced fat intake and absorption hence
reduced absorption of fat soluble vitamins. Thus reduction
of these immunologically active vitamins may predispose TB
patients to other infections or encourage development of
advance TB by causing low macrophage activation and
reduced production of antimicrobial factors.
The results of this study indicated the need for the integra-
tion of nutritional assessment and support into the clinical
management of TB patients in Nigeria. A previous study
reported reduced recurrence of TB with micronutrient supple-
mentation between 2–8 months after initiation of anti-TB
treatment among Tanzanian patients [31].
The present study showed that the levels of trace elements
(Fe, Zn and Cu) and vitamins (A, C, D and E) were lowest
at 2 months and 4 months of anti-TB drug therapy. This
may be due to drug-micronutrient interactions or drug-
induced nutrient depletion. The observation that micronutri-
ent levels were raised after 4 months of anti-TB chemotherapy
indicates adaptation of patients’ system to the drugs. Based on
this ﬁnding, it is recommended that vitamins and zinc
supplements be given along with anti-TB chemotherapy from
commencement of anti-TB drug therapy.
In conclusion, micronutrient malnutrition in TB patients
may contribute to advancement of latent TB to active TB
and possibly to drug-resistant TB and 2–4 months post com-
mencement of anti-TB drugs is very important for micronutri-
ent supplementation. Further studies are however required to
determine the dose of micronutrient (vitamins A, C, D, E
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